Advertisement
Australia markets closed
  • ALL ORDS

    7,897.50
    +48.10 (+0.61%)
     
  • ASX 200

    7,629.00
    +42.00 (+0.55%)
     
  • AUD/USD

    0.6612
    +0.0040 (+0.61%)
     
  • OIL

    77.99
    -0.96 (-1.22%)
     
  • GOLD

    2,310.10
    +0.50 (+0.02%)
     
  • Bitcoin AUD

    95,990.36
    +986.16 (+1.04%)
     
  • CMC Crypto 200

    1,317.57
    +40.59 (+3.18%)
     
  • AUD/EUR

    0.6140
    +0.0020 (+0.33%)
     
  • AUD/NZD

    1.0992
    -0.0017 (-0.16%)
     
  • NZX 50

    11,938.08
    +64.04 (+0.54%)
     
  • NASDAQ

    17,890.79
    +349.25 (+1.99%)
     
  • FTSE

    8,213.49
    +41.34 (+0.51%)
     
  • Dow Jones

    38,675.68
    +450.02 (+1.18%)
     
  • DAX

    18,001.60
    +105.10 (+0.59%)
     
  • Hang Seng

    18,475.92
    +268.79 (+1.48%)
     
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

Company News For Oct 24, 2019

  • Alexion Pharmaceuticals Inc.’s ALXN shares soared 7.4% after reporting third-quarter 2020 adjusted earnings per share of $2.79, surpassing the Zacks Consensual Estimate of $2.49.

  • Anthem Inc. ANTM gained 1.3% after the company posted third-quarter 2019 adjusted earnings per share of $4.87, beating the Zacks Consensus Estimate of $4.84.

  • Shares of Thermo Fisher Scientific Inc. TMO surged 5.7% after posting third-quarter 2019 adjusted earnings per share of $2.94, outpacing the Zacks Consensus Estimate of $2.88.

  • Boston Scientific Corp. BSX shares climbed 5% after the company reported third-quarter 2019 adjusted earnings per share of $0.39, a penny above the Zacks Consensus Estimate.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report
 
Boston Scientific Corporation (BSX) : Free Stock Analysis Report
 
Alexion Pharmaceuticals, Inc. (ALXN) : Free Stock Analysis Report
 
Anthem, Inc. (ANTM) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research